

Bruce Randazzo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2764992/publications.pdf>

Version: 2024-02-01

8

papers

1,864

citations

1163117

8

h-index

1588992

8

g-index

8

all docs

8

docs citations

8

times ranked

1345

citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study. Journal of Dermatological Treatment, 2022, 33, 2317-2324.	2.2	17
2	Maintenance of clinical response and consistent safety profile with up to 3Âyears of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. Journal of the American Academy of Dermatology, 2020, 82, 936-945.	1.2	71
3	Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet, The, 2019, 394, 831-839.	13.7	250
4	Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients with Moderate-to-Severe Plaque Psoriasis. Journal of Investigative Dermatology, 2019, 139, 1830-1834.e6.	0.7	22
5	Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions. JAMA Dermatology, 2018, 154, 676.	4.1	90
6	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatorâ€controlled VOYAGE 1 trial. Journal of the American Academy of Dermatology, 2017, 76, 405-417.	1.2	673
7	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparatorâ€controlled VOYAGE 2 trial. Journal of the American Academy of Dermatology, 2017, 76, 418-431.	1.2	554
8	Ustekinumab in adolescent patients age 12 to 17Âyears with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study. Journal of the American Academy of Dermatology, 2015, 73, 594-603.	1.2	187